EVALUATING THE OCCURRENCE OF ADVERSE EVENTS AMONG PEDIATRIC PATIENTS EXPOSED TO INTRAVENOUS LACOSAMIDE (VIMPATĀ®) USING REAL WORLD DATA First published 30/01/2020 Last updated 02/07/2024 EU PAS number:EUPAS32597 Study Finalised